Drug Trial Radar · NCT06941350
A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD
Last checked: Nov 19, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 28, 2025
Primary completion
Oct 30, 2026
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.
Conditions
- Acute Graft-versus-Host Disease
Interventions
NCR102 injectionBiological
Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event(AE) or Serious Adverse Event(SAE)Time frame: 100 days after first administration of NCR102 injection
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.